Login to Your Account



Index, Almirall in $138M European deal for Kappaproct

By Cormac Sheridan
Staff Writer

Tuesday, April 1, 2014
Index Pharmaceuticals AB is getting 5 million (US$6.9 million) up front and could get up to 95 million more in a European licensing deal with Almirall SA for its ulcerative colitis treatment, Kappaproct, which is undergoing a phase III trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription